Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to sign the ICF and agree to comply with the requirements of the study;~* Subjects with pathologically confirmed advanced solid tumors who have failed standard-of-care therapy, or have no standard-of-care therapy available, or are currently not eligible for standard-of-care therapy;~* ECOG performance status score of 0 to 1;~* Expected survival ≥ 3 months;~* With at least one measurable lesion per RECIST v1.1;~* Subjects should discontinue all anti-tumor therapies prior to receiving study treatment, and the toxicity caused by prior anti-tumor therapy has recovered to ≤ Grade 1 per CTCAE v5.0;~* The specific requirements of washout period should be met before first dose;~* Adequate organ function~* Female subjects of childbearing potential must have a negative pregnancy test prior to the first dose and are required to use effective contraception from signing the ICF until 6 months after the last dose of study treatment~Exclusion Criteria:~* Presence of risks that may significantly affect the absorption of the investigational product (e.g. inability to swallow, intestinal obstruction, chronic diarrhea, etc.);~* Having received immunotherapy and experienced ≥ Grade 3 immune-related adverse events (irAEs) or ≥ Grade 2 immune-related myocarditis;~* Having received systemic glucocorticoids (\> 10 mg/day of prednisone or equivalent) or other immunosuppressants within 14 days prior to the first dose of investigational product;~* Presence of symptomatic parenchymal brain metastasis or leptomeningeal metastasis;~* Active, or previous autoimmune disease with the potential for relapse (excluding well-controlled type 1 diabetes mellitus; manageable hypothyroidism with hormone replacement therapy only).;~* Any other malignancy (except cured basal cell carcinoma of skin and in-situ carcinoma of the cervix) within 3 years prior to the first dose;~* History of serious cardiovascular and cerebrovascular diseases;~* Presence of active interstitial lung disease or history of interstitial lung disease requiring glucocorticoid treatment;~* Presence of severe chronic or active infections (including tuberculosis infection, etc.) requiring intravenous antimicrobial, antifungal or antiviral therapy;~* Active HBV or HCV infection;~* History of immunodeficiency or organ transplantation;~* Presence of uncontrolled third spacing fluid;~* Concomitant diseases or any other conditions that may seriously jeopardize the subject's safety or affect the subject's completion of the study, at the discretion of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- RGT-264 monotherapy (Type: EXPERIMENTAL): The study is composed of dose escalation stage and dose expansion stage. RGT-264 will be administered orally daily alone as monotherapy in both stages. In the dose escalation stage, the subjects will receive once daily of RGT-264 monotherapy across approximately 6 ascending dose levels. The starting dose is 10 mg/day. In the dose expansion stage, the subjects will receive RGT-264 treatment at the recommended dose from dose escalation part.

Based on this trial design, predict the completion outcome and termination type (if applicable).